5-Aminosalicylates in inflammatory bowel disease: Choosing the right dose

Digestive and Liver Disease

Volumn 33, Issue 5, 2001, Pages 393-398

  Qasim, A ^a   Seery, J ^a   O'Morain, C A ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; CIPROFLOXACIN; CORTICOSTEROID; MESALAZINE; METRONIDAZOLE; MICROSPHERE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FECES LEVEL; DRUG FORMULATION; DRUG RELEASE; DRUG URINE LEVEL; END TO END ANASTOMOSIS; END TO SIDE ANASTOMOSIS; ENTERITIS; GASTROINTESTINAL TRACT; HUMAN; INTESTINE TRANSIT TIME; PH; RECURRENCE RISK; REVIEW; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; REMISSION INDUCTION;

EID: 0034923640     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis
2. A critical analysis of the use of salicyllazosulphapyridine in chronic ulcerative colitis
3. Controlled trial of sulphasalazine in the treatment of ulcerative colitis
4. A trial of sulfasalazine as adjunctive therapy in Crohn's disease
5. The mode of action of the aminosalicylates in inflammatory bowel disease
6. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease
7. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine
8. Mesalamine induced apoptosis of colorectal cancer: On the verge of a new chemopreventive era?
9. An experiment to determine the active therapeutic moiety of sulphasalazine
10. Comparison of delayed-release 5-aminosalicylic acid (mesalamine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis
11. Therapy of inflammatory bowel disease using new 5-ASA compounds: An introduction
12. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial
13. Sulfasalazine revisited: A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis
14. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study
15. 5-aminosalicylic acid as rectal enema in ulcerative colitis parents unable to take sulphasalazine
16. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine
17. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicylic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease
18. 5-aminosalicylate related renal dysfunction in IBD
19. An oral preparation to release drugs in the human colon
20. Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs
21. 5-Aminosalicylic acid in a slow-release preparation: Bioavailability, plasma level, and excretion in humans
22. Disposition of disodium azo-disalicylate in healthy subjects
23. Disopsition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers
24. Disposition of mesalamine from mesalamine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea
25. pH-profile and regional transit times of the normal gut measured by radiotelemetry device
26. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract
27. Gastrointestinal pH profile in patients with inflammatory bowel disease
28. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease
29. Dose loading with delayed-release mesalamine: A study of tissue concentration and standard pharmacokinetic parameters
30. Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis
31. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis
32. Anastomotic configuration and mucosal 5-aminosalicylic acid (5-ASA) concentrations in patients with Crohn's disease: A GISC study
33. Coated oral 5-amino-salicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study
34. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis
35. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study
36. Mesalamine capsules for treatment of active ulcerative colitis: Results of a controlled trial
37. Rectal corticosteroids versus alternative treatment in ulcerative colitis: A meta-analysis
38. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: Results of a multicentered placebo-controlled trial
39. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (salazopyrin)
40. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis
41. Comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months
42. Improved maintenance of remission in ulcerative colitis by balsalazide 4G/day compared to 2G/day
43. Optimum dose of olsalazine for maintaining remission in ulcerative colitis
44. Comparison of the efficacy and safety of 1.5 compared with 3 gm oral slow-release mesalamine (Pentasa) in the maintenance treatment of ulcerative colitis
45. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis
46. Controlled release mesalamine capsules for the maintenance of remission of ulcerative colitis patients
47. 5-aminosalicylic acid in the treatment of Crohn's disease. A 16 week double-blind, placebo-controlled, multicenter study with Pentasa
48. Slow-release 5-aminosalicylic acid (Pentasa) for the treatment of active Crohn's disease
49. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
50. Long-term management of Crohn's disease with mesalamine capsules (Pentasa)
51. Second trial of mesalamine therapy in the treatment of active Crohn's disease
52. A controlled trial comparing ciprofloxacin with mesalamine for the treatment of active Crohn's disease
53. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease
54. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: A multicentre placebo-controlled study
55. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease
56. 5-aminosalicylates for prevention of recurrence in patients with Crohn's disease: Time for a reappraisal?
57. A randomised, double-blind, placebo-controlled trial of oral 5-ASA (Asacol) in the treatment of symptomatic Crohn's colitis and ileocolitis
58. A controlled double blind multicentre study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission
59. National Co-operative Crohn's Disease Study: Results of drug treatment
60. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
61. Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables
62. Comparison between high-dose 5-aminosalicylic acid (5-ASA) and 6-methylprednisolone in active Crohn's disease
63. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: A multicentre trial
64. Placebo-controlled trial of Calversal (C) in the prevention of early endoscopic relapse after 'curative' resection for Crohn's disease (CD)
65. Delayed recurrence following surgery for Crohn's disease (CD)